Note | |
| |
Entity | Cervical cancer |
Note | WIF1 is downregulated by promoter hypermethylation in 87.5% of primary cervical cancer. Peritumoral WIF1 gene transfer induces apoptosis and inhibits growth and invasion (Ramachandran et al., 2011). |
| |
| |
Entity | Glioblastoma |
Note | WIF1 silencing is mediated by both deletion (7/69, 10%) and promoter hypermethylation (29/110, 26%). WIF1 re-expression abolishes tumorigenicity of glioblastoma cell lines potentially by inducing senescence (Lambiv et al., 2011). |
| |
| |
Entity | Primary non-small-cell lung carcinoma (NSCLC) |
Note | WIF1 is frequently downregulated and this downregulation is correlated with WIF1 promoter hypermethylation (Mazieres et al., 2004). |
| |
| |
Entity | Osteosarcoma |
Note | Hypermethylation of the WIF1 promoter is found in the majority of osteosarcoma cell lines tested and it correlates with WIF1 mRNA downregulation (Rubin et al., 2010). |
| |
| |
Entity | Hepatocellular carcinoma (HCC) |
Note | WIF1 is frequently downregulated through promoter hypermethylation (Deng et al., 2010). |
| |
| |
Entity | Mesothelioma |
Note | WIF-1 promoter methylation was reported from 73.9% of mesothelioma tissues and in 100% of tested mesothelioma cell lines (Kohno et al., 2010). |
| |
| |
Entity | Renal cell carcinoma (RCC) |
Note | WIF-1 is downregulated by promoter methylation and when re-expressed induces apoptosis in RCC cells (Kawakami et al., 2009). |
| |
| |
Entity | Bladder cancer |
Note | Epigenetic inactivation of WIF1 in bladder cancer deregulates WNT pathway activation. WIF1 re-expression induces a G1-arrest via p27 and p21 accumulation (Tang et al., 2009; Urakami et al., 2006). |
| |
| |
Entity | Esophageal adenocarcinoma (EAC) |
Note | Epigenetic alteration of WIF1 is an early event in the carcinogenesis of EAC. It's suggested to be involved in the progression from Barrett's esophagus (BE) to EAC thus WIF1 hypermethylation is proposed to be used as a diagnostic and predictive marker for increased EAC risk in BE patients. (Clément et al., 2008). |
| |
| |
Entity | Gastrointestinal cancers |
Note | WIF-1 expression has been reported to be downregulated in 80.0% of esophageal, 74.2% of gastric, 82.0% of colorectal, and 75% of pancreatic cancer tissues. WIF1 silencing, mediated by hypermethylation, is proposed to be an early event in colorectal carcinogenesis (Taniguchi et al., 2005). |
| |
| |
Entity | Breast cancer |
Note | 67% of the investigated invasive breast adenocarcinoma (Stages II or III) shows aberrant WIF1 promoter methylation (Ai et al., 2006). |
| |
| |
Entity | Salivary gland pleomorphic adenoma |
Note | WIF1 is rearranged resulting in a HMGA2/WIF1 fusion transcript. In consequence of this fusion WIF1 that in normal salivary gland tissue is highly expressed becomes downregulated. On the contrary, HMGA2 that in normal tissue is not expressed is strongly upregulated (Queimado et al., 2007). |
| |
Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. |
Ai L, Tao Q, Zhong S, Fields CR, Kim WJ, Lee MW, Cui Y, Brown KD, Robertson KD. |
Carcinogenesis. 2006 Jul;27(7):1341-8. Epub 2006 Feb 25. |
PMID 16501252 |
|
Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus. |
Clement G, Guilleret I, He B, Yagui-Beltran A, Lin YC, You L, Xu Z, Shi Y, Okamoto J, Benhattar J, Jablons D. |
Cancer Sci. 2008 Jan;99(1):46-53. Epub 2007 Nov 13. |
PMID 18005197 |
|
Epigenetic silencing of WIF-1 in hepatocellular carcinomas. |
Deng Y, Yu B, Cheng Q, Jin J, You H, Ke R, Tang N, Shen Q, Shu H, Yao G, Zhang Z, Qin W. |
J Cancer Res Clin Oncol. 2010 Aug;136(8):1161-7. Epub 2010 Jan 30. |
PMID 20119713 |
|
A new secreted protein that binds to Wnt proteins and inhibits their activities. |
Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB, Nathans J. |
Nature. 1999 Apr 1;398(6726):431-6. |
PMID 10201374 |
|
Functional significance of Wnt inhibitory factor-1 gene in kidney cancer. |
Kawakami K, Hirata H, Yamamura S, Kikuno N, Saini S, Majid S, Tanaka Y, Kawamoto K, Enokida H, Nakagawa M, Dahiya R. |
Cancer Res. 2009 Nov 15;69(22):8603-10. Epub 2009 Nov 3. |
PMID 19887605 |
|
Secreted antagonists of the Wnt signalling pathway. |
Kawano Y, Kypta R. |
J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34. |
PMID 12775774 |
|
Aberrant promoter methylation of WIF-1 and SFRP1, 2, 4 genes in mesothelioma. |
Kohno H, Amatya VJ, Takeshima Y, Kushitani K, Hattori N, Kohno N, Inai K. |
Oncol Rep. 2010 Aug;24(2):423-31. |
PMID 20596629 |
|
The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. |
Lambiv WL, Vassallo I, Delorenzi M, Shay T, Diserens AC, Misra A, Feuerstein B, Murat A, Migliavacca E, Hamou MF, Sciuscio D, Burger R, Domany E, Stupp R, Hegi ME. |
Neuro Oncol. 2011 Jul;13(7):736-47. Epub 2011 Jun 3. |
PMID 21642372 |
|
Modular mechanism of Wnt signaling inhibition by Wnt inhibitory factor 1. |
Malinauskas T, Aricescu AR, Lu W, Siebold C, Jones EY. |
Nat Struct Mol Biol. 2011 Jul 10;18(8):886-93. doi: 10.1038/nsmb.2081. |
PMID 21743455 |
|
Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. |
Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F, Jablons DM. |
Cancer Res. 2004 Jul 15;64(14):4717-20. |
PMID 15256437 |
|
WIF1, an inhibitor of the Wnt pathway, is rearranged in salivary gland tumors. |
Queimado L, Lopes CS, Reis AM. |
Genes Chromosomes Cancer. 2007 Mar;46(3):215-25. |
PMID 17171686 |
|
Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo. |
Ramachandran I, Thavathiru E, Ramalingam S, Natarajan G, Mills WK, Benbrook DM, Zuna R, Lightfoot S, Reis A, Anant S, Queimado L. |
Oncogene. 2012 May 31;31(22):2725-37. doi: 10.1038/onc.2011.455. Epub 2011 Oct 17. |
PMID 22002305 |
|
Cloning and characterization of the promoter of human Wnt inhibitory factor-1. |
Reguart N, He B, Xu Z, You L, Lee AY, Mazieres J, Mikami I, Batra S, Rosell R, McCormick F, Jablons DM. |
Biochem Biophys Res Commun. 2004 Oct 8;323(1):229-34. |
PMID 15351726 |
|
Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. |
Rubin EM, Guo Y, Tu K, Xie J, Zi X, Hoang BH. |
Mol Cancer Ther. 2010 Mar;9(3):731-41. Epub 2010 Mar 2. |
PMID 20197388 |
|
WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. |
Tang Y, Simoneau AR, Liao WX, Yi G, Hope C, Liu F, Li S, Xie J, Holcombe RF, Jurnak FA, Mercola D, Hoang BH, Zi X. |
Mol Cancer Ther. 2009 Feb;8(2):458-68. Epub 2009 Jan 27. |
PMID 19174556 |
|
Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. |
Taniguchi H, Yamamoto H, Hirata T, Miyamoto N, Oki M, Nosho K, Adachi Y, Endo T, Imai K, Shinomura Y. |
Oncogene. 2005 Nov 24;24(53):7946-52. |
PMID 16007117 |
|
Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. |
Urakami S, Shiina H, Enokida H, Kawakami T, Tokizane T, Ogishima T, Tanaka Y, Li LC, Ribeiro-Filho LA, Terashima M, Kikuno N, Adachi H, Yoneda T, Kishi H, Shigeno K, Konety BR, Igawa M, Dahiya R. |
Clin Cancer Res. 2006 Jan 15;12(2):383-91. |
PMID 16428476 |
|